Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinic… Read more
Omeros Corporation (OMER) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.084x
Based on the latest financial reports, Omeros Corporation (OMER) has a cash flow conversion efficiency ratio of 0.084x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.47 Million) by net assets ($-220.48 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Omeros Corporation - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Omeros Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Omeros Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Omeros Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wuxi Huadong Heavy Machinery Co Ltd
SHE:002685
|
0.044x |
|
Camden National Corporation
NASDAQ:CAC
|
-0.025x |
|
Bank of Xi'An Co Ltd
SHG:600928
|
-0.090x |
|
XERIS BIOPH.HOL. DL-0001
F:2B30
|
N/A |
|
Theon International Plc
AS:THEON
|
-0.012x |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771
|
0.067x |
|
Pursuit Attractions and Hospitality, Inc.
NYSE:PRSU
|
0.149x |
|
Elang Mahkota Teknologi Tbk
JK:EMTK
|
-0.013x |
Annual Cash Flow Conversion Efficiency for Omeros Corporation (2007–2024)
The table below shows the annual cash flow conversion efficiency of Omeros Corporation from 2007 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-182.61 Million | $-148.80 Million | 0.815x | +127.24% |
| 2023-12-31 | $-24.98 Million | $74.73 Million | -2.991x | -196.34% |
| 2022-12-31 | $85.68 Million | $-86.48 Million | -1.009x | +78.12% |
| 2021-12-31 | $23.78 Million | $-109.72 Million | -4.614x | -656.68% |
| 2020-12-31 | $-120.75 Million | $-100.09 Million | 0.829x | +50.42% |
| 2019-12-31 | $-109.02 Million | $-60.07 Million | 0.551x | +153.20% |
| 2018-12-31 | $100.16 Million | $-103.74 Million | -1.036x | -108.05% |
| 2017-12-31 | $-2.81 Million | $-36.23 Million | 12.874x | +836.02% |
| 2016-12-31 | $-37.45 Million | $-51.50 Million | 1.375x | -44.67% |
| 2015-12-31 | $-26.23 Million | $-65.21 Million | 2.486x | +82.66% |
| 2014-12-31 | $-42.65 Million | $-58.04 Million | 1.361x | -15.75% |
| 2013-12-31 | $-18.38 Million | $-29.70 Million | 1.615x | +903.15% |
| 2012-12-31 | $-214.58 Million | $-34.55 Million | 0.161x | -96.52% |
| 2011-12-31 | $-5.55 Million | $-25.67 Million | 4.622x | +752.34% |
| 2010-12-31 | $20.47 Million | $-14.50 Million | -0.708x | -60.65% |
| 2009-12-31 | $43.15 Million | $-19.03 Million | -0.441x | -304.36% |
| 2008-12-31 | $-91.17 Million | $-19.67 Million | 0.216x | +5.44% |
| 2007-12-31 | $-69.94 Million | $-14.31 Million | 0.205x | -- |